A Japanese traditional medicine Hochuekkito promotes negative conversion of vancomycin-resistant Enterococci.
Aged
Aged, 80 and over
Anti-Bacterial Agents
/ pharmacology
Cross Infection
/ drug therapy
Drug Resistance, Bacterial
/ drug effects
Drugs, Chinese Herbal
/ metabolism
Enterococcus
/ drug effects
Female
Gram-Positive Bacterial Infections
/ microbiology
Humans
Japan
/ epidemiology
Male
Medicine, Chinese Traditional
/ methods
Medicine, East Asian Traditional
/ methods
Medicine, Kampo
/ methods
Middle Aged
Probiotics
/ therapeutic use
Retrospective Studies
Vancomycin
/ pharmacology
Vancomycin-Resistant Enterococci
/ drug effects
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
28 05 2021
28 05 2021
Historique:
received:
10
10
2020
accepted:
04
05
2021
entrez:
29
5
2021
pubmed:
30
5
2021
medline:
20
11
2021
Statut:
epublish
Résumé
Vancomycin-resistant enterococci (VRE) are prominent causes of nosocomial infections. Japanese traditional (Kampo) medicine promotes intestinal immunity and protects against bacterial infections. We assessed potential differences in the clinical course of VRE-positive patients, based on their characteristics and treatment with Kampo medicines. This retrospective observational study collected data from VRE-positive patients from August 2018 to July 2019 at a tertiary-care hospital in Japan. The data of 122 consecutive VRE-positive inpatients were analyzed. Sixty-nine patients were treated with probiotics, among whom, 18 were further treated with Kampo medicines. Twenty-six of the 122 patients subsequently died. In univariate analyses, subsequent VRE negative conversion significantly reduced the mortality of VRE-detected patients (p = .0003). Administration of probiotics (p = .0065) and Kampo medicines with probiotics (p = .0002), especially of the Kampo medicine hochuekkito (p = .0014), and a higher serum albumin level positively contributed to the subsequent VRE negative conversion. Multivariate analyses demonstrated that Kampo medicines and body mass index contributed to VRE negative conversion. Hochuekkito shortened the time needed for VRE negative conversion (p = 0.0485). Administration of Kampo medicines, especially of hochuekkito, in addition to probiotics in VRE patients may promote VRE negative conversion.
Identifiants
pubmed: 34050227
doi: 10.1038/s41598-021-90890-4
pii: 10.1038/s41598-021-90890-4
pmc: PMC8163788
doi:
Substances chimiques
Anti-Bacterial Agents
0
Drugs, Chinese Herbal
0
bu-zhong-yi-qi-tang
0
Vancomycin
6Q205EH1VU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
11300Références
Evid Based Complement Alternat Med. 2019 Sep 2;2019:9590260
pubmed: 31565066
J Infect Chemother. 2003 Mar;9(1):58-61
pubmed: 12673409
Front Nutr. 2020 Jul 15;7:86
pubmed: 32766269
Antimicrob Agents Chemother. 2015 Aug;59(8):4593-9
pubmed: 26014940
J Clin Gastroenterol. 2011 Nov-Dec;45(10):872-7
pubmed: 21814146
Asian Pac J Allergy Immunol. 2010 Mar;28(1):59-66
pubmed: 20527518
Anaerobe. 2017 Oct;47:94-103
pubmed: 28465256
Antimicrob Agents Chemother. 1998 Aug;42(8):2150
pubmed: 9722470
Eur J Clin Microbiol Infect Dis. 2012 Jun;31(6):1095-100
pubmed: 21968723
Med J Aust. 2007 May 7;186(9):454-7
pubmed: 17484706
Sci Rep. 2021 Feb 25;11(1):4580
pubmed: 33633259
Ther Clin Risk Manag. 2019 Feb 27;15:343-354
pubmed: 30881000
Arch Microbiol. 2017 Sep;199(7):953-961
pubmed: 28634691
PLoS One. 2012;7(2):e31700
pubmed: 22384059
Geriatr Gerontol Int. 2017 May;17(5):679-688
pubmed: 27273639
Geriatr Gerontol Int. 2016 Sep;16(9):983-1001
pubmed: 27594406
Curr Infect Dis Rep. 2019 May 22;21(7):22
pubmed: 31119397
J Pharm Biomed Anal. 2019 Jul 15;171:81-98
pubmed: 30981193
Evid Based Complement Alternat Med. 2010 Mar;7(1):69-77
pubmed: 18955273
Front Nutr. 2018 Jul 23;5:66
pubmed: 30083536
J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Feb 15;1044-1045:177-184
pubmed: 28113140
Evid Based Complement Alternat Med. 2018 Feb 22;2018:7415975
pubmed: 29681983
Br J Nutr. 2004 Jul;92(1):105-11
pubmed: 15230993